Vaxcyte (PCVX) Financials

$35.44 -1.76 (-4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$35.41 -0.03 (-0.08%)

As of 04:40 PM Eastern

Annual Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-29	-50	-89	-100	-223	-402	-464
Consolidated Net Income / (Loss)	-29	-50	-89	-100	-223	-402	-464
Net Income / (Loss) Continuing Operations	-29	-50	-89	-100	-223	-402	-464
Total Pre-Tax Income	-29	-50	-89	-100	-223	-402	-464
Total Operating Income	-36	-54	-90	-104	-232	-468	-570
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	36	54	90	104	232	468	570
Selling, General & Admin Expense	5.39	8.55	16	25	40	61	93
Research & Development Expense	30	46	74	78	169	332	477
Other Operating Expenses / (Income)	-	-	-	0.00	23	75	0.00
Total Other Income / (Expense), net	6.05	4.34	0.36	3.59	8.77	66	106
Interest Expense	0.08	0.04	0.01	0.01	0.00	0.00	0.00
Interest & Investment Income	0.90	0.63	0.24	0.35	8.36	63	110
Other Income / (Expense), net	5.22	3.74	0.13	3.25	0.42	2.87	-4.38
Basic Earnings per Share	($8.12)	($13.25)	($3.02)	($1.93)	($3.44)	($4.14)	($3.80)
Weighted Average Basic Shares Outstanding	3.63M	3.80M	29.55M	51.92M	64.88M	97.16M	122.00M
Diluted Earnings per Share	($8.12)	($13.25)	($3.02)	($1.93)	($3.44)	($4.14)	($3.80)
Weighted Average Diluted Shares Outstanding	3.63M	3.80M	29.55M	51.92M	64.88M	97.16M	122.00M
Weighted Average Basic & Diluted Shares Outstanding	3.63M	3.80M	29.55M	51.92M	80.03M	108.41M	128.76M
Cash Dividends to Common per Share	-	-	$0.00	$0.00	$0.00	$0.00	$0.00

This table shows Vaxcyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Consolidated Net Income / (Loss)	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Net Income / (Loss) Continuing Operations	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Total Pre-Tax Income	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Total Operating Income	-59	-87	-71	-87	-113	-197	-114	-153	-140	-162	-181
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	59	87	71	87	113	197	114	153	140	162	181
Selling, General & Admin Expense	11	12	13	14	16	18	20	21	23	29	33
Research & Development Expense	48	52	58	73	97	104	95	132	117	134	148
Total Other Income / (Expense), net	0.66	8.22	11	19	20	16	19	24	37	25	40
Interest & Investment Income	1.19	6.63	11	16	18	17	22	24	28	36	33
Other Income / (Expense), net	-0.53	1.59	-0.32	2.36	1.87	-1.04	-2.34	0.44	8.74	-11	7.14
Basic Earnings per Share	($0.93)	($1.03)	($0.70)	($0.70)	($0.91)	($1.83)	($0.85)	($1.10)	($0.83)	($1.02)	($1.04)
Weighted Average Basic Shares Outstanding	61.99M	64.88M	86.21M	98.06M	101.67M	97.16M	111.69M	117.26M	123.69M	122.00M	135.69M
Diluted Earnings per Share	($0.93)	($1.03)	($0.70)	($0.70)	($0.91)	($1.83)	($0.85)	($1.10)	($0.83)	($1.02)	($1.04)
Weighted Average Diluted Shares Outstanding	61.99M	64.88M	86.21M	98.06M	101.67M	97.16M	111.69M	117.26M	123.69M	122.00M	135.69M
Weighted Average Basic & Diluted Shares Outstanding	78.98M	80.03M	93.71M	93.85M	95.15M	108.41M	108.80M	111.61M	124.64M	128.76M	129.00M

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	30	-7.11	327	-316	766	-437	-9.36
Net Cash From Operating Activities	-30	-47	-47	-121	-171	-297	-453
Net Cash From Continuing Operating Activities	-30	-47	-47	-121	-171	-297	-453
Net Income / (Loss) Continuing Operations	-29	-50	-89	-100	-223	-402	-464
Consolidated Net Income / (Loss)	-29	-50	-89	-100	-223	-402	-464
Depreciation Expense	1.04	1.23	1.41	1.80	2.83	3.16	7.00
Amortization Expense	-	0.00	0.00	3.06	5.67	-28	-30
Non-Cash Adjustments To Reconcile Net Income	-4.76	1.96	13	2.25	35	77	16
Changes in Operating Assets and Liabilities, net	2.75	-0.06	28	-28	8.91	54	18
Net Cash From Investing Activities	-1.77	-1.20	-1.11	-212	75	-773	-2,006
Net Cash From Continuing Investing Activities	-1.77	-1.20	-1.11	-212	75	-773	-2,006
Purchase of Property, Plant & Equipment	-1.77	-1.20	-1.16	-6.56	-5.84	-16	-22
Purchase of Investments	-	0.00	0.00	-336	-103	-1,330	-3,087
Sale and/or Maturity of Investments	-	0.00	0.00	131	183	624	1,200
Other Investing Activities, net	-	-	-	0.00	0.00	-52	-97
Net Cash From Financing Activities	62	42	375	18	862	640	2,449
Net Cash From Continuing Financing Activities	62	42	375	18	862	640	2,449
Issuance of Common Equity	0.12	0.12	0.41	15	862	644	2,463
Other Financing Activities, net	-0.28	-1.05	0.57	3.01	-0.86	-3.88	-14
Effect of Exchange Rate Changes	-	-0.34	0.09	-0.44	0.14	-6.69	0.43

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	40	556	-454	151	14	-148	214	-93	532	-662	-41
Net Cash From Operating Activities	-39	-65	-48	-63	-58	-129	-159	-121	-61	-111	-166
Net Cash From Continuing Operating Activities	-39	-65	-48	-63	-58	-129	-159	-121	-61	-111	-166
Net Income / (Loss) Continuing Operations	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Consolidated Net Income / (Loss)	-58	-78	-60	-68	-93	-181	-95	-129	-103	-137	-141
Depreciation Expense	0.68	0.96	0.71	0.75	0.81	0.89	1.00	1.35	1.79	2.86	2.96
Amortization Expense	1.43	0.42	-4.36	-10	-13	-0.31	-8.90	-7.81	-3.40	-9.76	-3.00
Non-Cash Adjustments To Reconcile Net Income	12	13	16	12	41	7.51	-34	57	26	-33	15
Changes in Operating Assets and Liabilities, net	5.17	-1.30	0.08	3.08	6.48	44	-22	-43	18	66	-40
Net Cash From Investing Activities	35	-36	-448	-334	22	-14	-451	-80	-917	-557	123
Net Cash From Continuing Investing Activities	35	-36	-448	-334	22	-14	-451	-80	-917	-557	123
Purchase of Property, Plant & Equipment	-0.84	-1.14	-5.61	2.14	-7.34	-5.25	-5.68	-7.78	-4.95	-4.02	-5.42
Purchase of Investments	-18	-71	-484	-433	-210	-204	-688	-351	-1,233	-815	-314
Sale and/or Maturity of Investments	53	36	41	97	239	247	249	309	354	288	465
Other Investing Activities, net	-	-	0.00	-	-	-52	-6.39	-31	-33	-26	-21
Net Cash From Financing Activities	44	657	42	547	49	2.74	818	110	1,515	4.91	0.76
Net Cash From Continuing Financing Activities	44	657	42	547	49	2.74	818	110	1,515	4.91	0.76
Issuance of Common Equity	43	659	42	546	49	6.61	816	108	1,513	25	0.00
Other Financing Activities, net	0.90	-2.36	-0.23	0.67	-0.45	-3.87	1.72	2.18	2.40	-21	0.76
Effect of Exchange Rate Changes	0.05	0.80	0.02	-0.08	1.05	-7.68	6.06	-1.41	-5.58	1.35	1.17

This table presents Vaxcyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	66	393	324	1,006	1,408	3,511
Total Current Assets	62	389	256	943	1,096	1,788
Cash & Equivalents	59	386	69	835	397	388
Short-Term Investments	-	0.00	177	97	683	1,359
Prepaid Expenses	2.75	2.80	10	11	16	41
Plant, Property, & Equipment, net	3.39	3.27	7.95	10	80	198
Total Noncurrent Assets	0.58	0.55	60	53	232	1,525
Long-Term Investments	-	0.00	27	27	163	1,388
Other Noncurrent Operating Assets	0.58	0.55	33	27	70	138
Total Liabilities & Shareholders' Equity	66	393	324	1,006	1,408	3,511
Total Liabilities	12	47	40	53	167	205
Total Current Liabilities	11	47	29	41	145	140
Accounts Payable	3.38	30	6.76	9.80	15	48
Accrued Expenses	7.08	17	13	24	113	65
Current Employee Benefit Liabilities	0.41	0.28	3.46	1.18	11	21
Other Current Liabilities	0.16	0.00	5.28	5.91	7.11	5.89
Total Noncurrent Liabilities	0.71	0.12	12	12	22	65
Other Noncurrent Operating Liabilities	0.69	0.11	12	12	22	65
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-106	346	284	954	1,240	3,306
Total Preferred & Common Equity	-106	346	284	954	1,240	3,306
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-106	346	284	954	1,240	3,306
Common Stock	2.97	544	583	1,476	2,165	4,698
Retained Earnings	-109	-199	-299	-522	-924	-1,388
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.24	-0.36	0.18	-3.87

This table presents Vaxcyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	412	1,008	1,503	1,496	2,091	2,087	3,560	3,378
Total Current Assets	370	841	1,310	1,295	1,517	1,481	2,214	1,717
Cash & Equivalents	278	380	531	545	612	519	1,050	347
Short-Term Investments	84	442	756	721	875	934	1,130	1,325
Prepaid Expenses	7.53	19	23	30	31	29	33	45
Plant, Property, & Equipment, net	9.95	15	16	11	85	126	163	217
Total Noncurrent Assets	32	152	176	189	489	480	1,183	1,444
Long-Term Investments	3.98	128	154	169	413	399	1,093	1,279
Other Noncurrent Operating Assets	28	24	22	21	76	81	90	165
Total Liabilities & Shareholders' Equity	412	1,008	1,503	1,496	2,091	2,087	3,560	3,378
Total Liabilities	53	63	69	93	107	101	142	178
Total Current Liabilities	39	53	60	86	87	83	124	97
Accounts Payable	5.49	12	16	16	22	10	18	21
Accrued Expenses	24	33	34	57	55	59	84	64
Current Employee Benefit Liabilities	3.45	1.88	4.42	6.93	3.09	6.46	12	5.99
Other Current Liabilities	6.43	5.95	5.99	6.03	7.20	7.29	9.64	6.13
Total Noncurrent Liabilities	13	11	9.23	7.78	20	18	18	81
Other Noncurrent Operating Liabilities	13	11	9.23	7.78	20	18	18	81
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	359	945	1,433	1,403	1,984	1,986	3,418	3,200
Total Preferred & Common Equity	359	945	1,433	1,403	1,984	1,986	3,418	3,200
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	359	945	1,433	1,403	1,984	1,986	3,418	3,200
Common Stock	804	1,527	2,087	2,149	3,001	3,132	4,669	4,729
Retained Earnings	-444	-583	-651	-744	-1,019	-1,148	-1,251	-1,529
Accumulated Other Comprehensive Income / (Loss)	-0.66	0.05	-2.52	-2.29	2.89	1.82	0.14	-0.32

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-67.98%	-79.05%	-8.52%	-133.73%	-119.30%	-21.85%
EBIT Growth	0.00%	-66.30%	-77.46%	-12.25%	-130.88%	-100.64%	-23.38%
NOPAT Growth	0.00%	-52.40%	-65.42%	-15.73%	-124.03%	-101.52%	-21.69%
Net Income Growth	0.00%	-70.51%	-77.46%	-12.17%	-123.31%	-80.00%	-15.33%
EPS Growth	0.00%	-63.18%	77.21%	36.09%	-78.24%	-20.35%	8.21%
Operating Cash Flow Growth	0.00%	-54.75%	1.10%	-160.34%	-40.53%	-73.97%	-52.51%
Free Cash Flow Firm Growth	0.00%	0.00%	16.67%	-352.22%	-18.96%	-123.64%	-73.66%
Invested Capital Growth	0.00%	0.00%	-700.89%	127.09%	-139.45%	43.55%	7,129.62%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-8.74%	-33.95%	-30.09%	2.75%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-9.90%	-32.06%	-31.99%	4.07%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-11.14%	-32.32%	-30.76%	5.71%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-8.48%	-28.44%	-34.31%	8.61%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-143.57%	-16.22%	-23.95%	17.57%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	7.24%	-49.74%	-9.03%	-27.27%	3.70%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-14.81%	-45.85%	4.47%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	188.47%	37.43%	92.28%	18.33%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.92%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	97.27%	98.83%	99.74%	99.66%	96.40%	86.48%	80.83%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-93.21%	-44.63%	-31.78%	-36.12%	-36.67%	-20.41%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-1,133.08%	0.00%	0.00%	-334.43%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	183.82%	-26.74%	-31.78%	-36.12%	-36.67%	-20.41%
Return on Equity Simple (ROE_SIMPLE)	0.00%	47.26%	-25.80%	-35.24%	-23.44%	-32.43%	-14.03%
Net Operating Profit after Tax (NOPAT)	-25	-38	-63	-73	-163	-328	-399
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	-41.94%	-11.91%	-8.34%	-9.90%	-6.78%	-2.98%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-17.05%	-26.41%	-12.06%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-30	-50	-89	-100	-232	-465	-574
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-49	-88	-96	-223	-490	-597
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.91	4.42	3.97	4.82	3.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.91	4.42	3.97	4.82	3.09
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	89.90	0.00	0.00	41.31
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.09	-1.11	-1.05	-0.99	-1.00	-0.96
Leverage Ratio	0.00	1.22	1.15	1.14	1.08	1.10	1.08
Compound Leverage Factor	0.00	1.20	1.14	1.13	1.04	0.95	0.87
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	297.22%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-197.22%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	10.35	16.87	17.22	42.82	20.21	29.26
Noncontrolling Interest Sharing Ratio	0.00%	297.22%	40.10%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	5.58	8.30	8.93	23.26	7.54	12.75
Quick Ratio	0.00	5.34	8.24	8.57	22.98	7.43	12.46
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-33	-27	-124	-147	-330	-572
Operating Cash Flow to CapEx	-1,718.33%	-3,945.19%	-4,219.73%	-1,859.29%	-2,920.68%	-1,847.78%	-2,018.22%
Free Cash Flow to Firm to Interest Expense	0.00	-821.70	-3,912.67	-17,693.86	-73,668.10	0.00	0.00
Operating Cash Flow to Interest Expense	-406.21	-1,178.63	-6,661.14	-17,341.86	-85,298.50	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-429.85	-1,208.50	-6,819.00	-18,274.57	-88,219.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	-5.04	-40	11	-4.31	-2.43	171
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-5.04	-35	51	-15	1.88	174
Enterprise Value (EV)	0.00	381	968	983	2,829	4,733	7,068
Market Capitalization	280	280	1,354	1,256	3,787	5,976	10,203
Book Value per Share	$0.00	($28.03)	$6.79	$5.38	$12.07	$13.04	$26.52
Tangible Book Value per Share	$0.00	($28.03)	$6.79	$5.38	$12.07	$13.04	$26.52
Total Capital	0.00	54	346	284	954	1,240	3,306
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-59	-386	-273	-958	-1,243	-3,135
Capital Expenditures (CapEx)	1.77	1.20	1.11	6.53	5.84	16	22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-8.31	-44	-18	-29	-130	-99
Debt-free Net Working Capital (DFNWC)	0.00	51	342	228	902	951	1,648
Net Working Capital (NWC)	0.00	51	342	228	902	951	1,648
Net Nonoperating Expense (NNE)	4.61	12	27	28	61	75	65
Net Nonoperating Obligations (NNO)	0.00	-59	-386	-273	-958	-1,243	-3,135
Total Depreciation and Amortization (D&A)	1.04	1.23	1.41	4.86	8.51	-25	-23
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($1.93)	($3.44)	($4.14)	($3.80)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	56.31M	64.88M	97.16M	122.00M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($1.93)	($3.44)	($4.14)	($3.80)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	56.31M	64.88M	97.16M	122.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($1.93)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	51.92M	80.03M	108.41M	128.76M
Normalized Net Operating Profit after Tax (NOPAT)	-25	-38	-63	-73	-163	-328	-399
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-404.17	-1,260.23	-12,779.14	-14,345.14	-115,919.50	0.00	0.00
NOPAT to Interest Expense	-331.64	-947.68	-8,958.10	-10,367.00	-81,289.60	0.00	0.00
EBIT Less CapEx to Interest Expense	-427.81	-1,290.10	-12,937.00	-15,277.86	-118,840.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-355.28	-977.55	-9,115.96	-11,299.71	-84,210.10	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-124.52%	-209.66%	-108.02%	-102.17%	-116.26%	-135.81%	-65.94%	-68.73%	-7.74%	8.55%	-39.42%
EBIT Growth	-121.63%	-196.11%	-84.21%	-73.29%	-88.06%	-132.65%	-63.35%	-79.91%	-18.01%	12.31%	-48.82%
NOPAT Growth	-117.35%	-190.06%	-81.52%	-81.99%	-92.95%	-127.18%	-60.79%	-75.54%	-23.80%	17.55%	-57.94%
Net Income Growth	-117.61%	-173.26%	-55.09%	-40.81%	-59.99%	-131.65%	-57.16%	-88.33%	-11.29%	24.18%	-48.09%
EPS Growth	-82.35%	-87.27%	-2.94%	12.50%	2.15%	-77.67%	-21.43%	-57.14%	8.79%	44.26%	-22.35%
Operating Cash Flow Growth	-35.66%	-27.65%	-72.15%	-60.36%	-49.29%	-97.50%	-233.66%	-93.48%	-5.49%	13.52%	-4.49%
Free Cash Flow Firm Growth	-17.69%	37.16%	52.23%	22.59%	-17.24%	-207.67%	-351.24%	-413.30%	-403.09%	-105.70%	-72.11%
Invested Capital Growth	44.22%	-139.45%	-170.53%	-244.27%	-357.52%	43.55%	1,757.18%	1,909.98%	558.57%	7,129.62%	195.97%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-22.27%	-46.69%	10.38%	-25.38%	-30.79%	-59.95%	36.74%	-27.49%	16.48%	-35.76%	3.65%
EBIT Q/Q Growth	-20.80%	-43.78%	15.85%	-18.57%	-31.10%	-77.87%	40.92%	-30.59%	14.00%	-32.17%	-0.15%
NOPAT Q/Q Growth	-22.33%	-47.79%	17.77%	-22.41%	-29.70%	-74.01%	41.80%	-33.64%	8.54%	-15.90%	-11.48%
Net Income Q/Q Growth	-19.34%	-34.76%	22.53%	-13.03%	-35.59%	-95.11%	47.45%	-35.45%	19.87%	-32.93%	-2.65%
EPS Q/Q Growth	-16.25%	-10.75%	32.04%	0.00%	-30.00%	-101.10%	53.55%	-29.41%	24.55%	-22.89%	-1.96%
Operating Cash Flow Q/Q Growth	1.48%	-69.19%	26.88%	-31.56%	8.28%	-123.83%	-23.53%	23.71%	49.99%	-83.50%	-49.26%
Free Cash Flow Firm Q/Q Growth	25.75%	2.39%	17.22%	-29.04%	-12.44%	-156.16%	-21.41%	-46.78%	-10.21%	-4.74%	-1.58%
Invested Capital Q/Q Growth	-234.11%	37.43%	-17.86%	-45.89%	-325.30%	92.28%	3,560.07%	59.34%	7.75%	18.33%	45.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	99.62%	100.00%	100.00%	100.00%	100.00%	100.00%	99.98%	100.00%	100.02%	100.00%
Interest Burden Percent	97.99%	92.19%	84.55%	80.60%	83.36%	91.45%	81.34%	84.39%	78.61%	79.05%	81.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-52.31%	-36.12%	-37.56%	-29.42%	-34.00%	-36.67%	-29.83%	-29.08%	-21.06%	-20.41%	-19.66%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-531.03%	-406.59%	-414.24%	-334.43%	-365.93%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-52.31%	-36.12%	-37.56%	-29.42%	-34.00%	-36.67%	-29.83%	-29.08%	-21.06%	-20.41%	-19.66%
Return on Equity Simple (ROE_SIMPLE)	-48.43%	0.00%	-25.93%	-18.47%	-21.35%	0.00%	-22.02%	-25.03%	-14.85%	0.00%	-15.93%
Net Operating Profit after Tax (NOPAT)	-41	-61	-50	-61	-79	-138	-80	-107	-98	-114	-127
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.94%	-2.84%	-1.63%	-0.81%	-1.50%	-3.92%	-1.05%	-1.31%	-0.22%	-1.08%	-0.58%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.35%	-	-	-	-11.10%	-	-	-	-3.43%	-3.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-59	-85	-72	-85	-111	-198	-117	-153	-131	-173	-174
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-57	-84	-75	-94	-123	-197	-125	-159	-133	-180	-174
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.96	3.97	3.18	3.26	3.41	4.82	3.28	4.14	3.73	3.09	1.52
Price to Tangible Book Value (P/TBV)	3.96	3.97	3.18	3.26	3.41	4.82	3.28	4.14	3.73	3.09	1.52
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	54.62	47.42	65.57	41.31	7.67
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-0.99	-1.00	-1.00	-1.02	-1.00	-0.97	-0.96	-0.98	-0.96	-0.94
Leverage Ratio	1.15	1.08	1.08	1.06	1.08	1.10	1.06	1.05	1.05	1.08	1.06
Compound Leverage Factor	1.13	0.99	0.91	0.86	0.90	1.01	0.86	0.89	0.82	0.86	0.86
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	15.17	43.30	28.29	40.64	30.78	20.84	36.29	48.53	53.94	29.64	16.15
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.41	23.26	15.94	21.76	15.14	7.54	17.42	17.88	17.88	12.75	17.70
Quick Ratio	9.21	22.98	15.58	21.37	14.79	7.43	17.07	17.53	17.61	12.46	17.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-46	-45	-38	-48	-54	-140	-169	-249	-274	-287	-292
Operating Cash Flow to CapEx	-4,572.72%	-5,721.14%	-850.24%	0.00%	-784.14%	-2,451.66%	-2,802.47%	-1,560.13%	-1,227.17%	-2,770.48%	-3,065.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-6.89	-4.31	-5.08	-7.41	-32	-2.43	84	134	145	171	249
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	5.46	-15	-12	-13	-25	1.88	89	142	176	174	165
Enterprise Value (EV)	1,057	2,829	2,050	3,239	3,350	4,733	4,600	6,363	9,481	7,068	1,911
Market Capitalization	1,424	3,787	3,000	4,680	4,784	5,976	6,500	8,215	12,754	10,203	4,862
Book Value per Share	$6.06	$12.07	$11.80	$15.30	$14.95	$13.04	$17.76	$18.26	$30.62	$26.52	$24.85
Tangible Book Value per Share	$6.06	$12.07	$11.80	$15.30	$14.95	$13.04	$17.76	$18.26	$30.62	$26.52	$24.85
Total Capital	359	954	945	1,433	1,403	1,240	1,984	1,986	3,418	3,306	3,200
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-366	-958	-950	-1,441	-1,434	-1,243	-1,900	-1,852	-3,273	-3,135	-2,951
Capital Expenditures (CapEx)	0.84	1.14	5.61	-2.14	7.34	5.25	5.68	7.78	4.95	4.02	5.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-32	-29	-34	-37	-56	-130	-57	-54	-90	-99	-52
Debt-free Net Working Capital (DFNWC)	330	902	788	1,250	1,210	951	1,430	1,399	2,090	1,648	1,620
Net Working Capital (NWC)	330	902	788	1,250	1,210	951	1,430	1,399	2,090	1,648	1,620
Net Nonoperating Expense (NNE)	17	17	11	7.34	14	43	15	22	5.18	24	14
Net Nonoperating Obligations (NNO)	-366	-958	-950	-1,441	-1,434	-1,243	-1,900	-1,852	-3,273	-3,135	-2,951
Total Depreciation and Amortization (D&A)	2.12	1.38	-3.65	-9.44	-12	0.58	-7.90	-6.46	-1.61	-6.89	-0.04
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.93)	($1.03)	($0.70)	($0.70)	($0.91)	($1.83)	($0.85)	($1.10)	($0.83)	($1.02)	($1.04)
Adjusted Weighted Average Basic Shares Outstanding	61.99M	64.88M	86.21M	98.06M	101.67M	97.16M	111.69M	117.26M	123.69M	122.00M	135.69M
Adjusted Diluted Earnings per Share	($0.93)	($1.03)	($0.70)	($0.70)	($0.91)	($1.83)	($0.85)	($1.10)	($0.83)	($1.02)	($1.04)
Adjusted Weighted Average Diluted Shares Outstanding	61.99M	64.88M	86.21M	98.06M	101.67M	97.16M	111.69M	117.26M	123.69M	122.00M	135.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.98M	80.03M	93.71M	93.85M	95.15M	108.41M	108.80M	111.61M	124.64M	128.76M	129.00M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-61	-50	-61	-79	-138	-80	-107	-98	-114	-127
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Vaxcyte's Financials

When does Vaxcyte's financial year end?

According to the most recent income statement we have on file, Vaxcyte's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Vaxcyte's net income changed over the last 6 years?

Vaxcyte's net income appears to be on an upward trend, with a most recent value of -$463.93 million in 2024, rising from -$29.49 million in 2018. The previous period was -$402.27 million in 2023. See where experts think Vaxcyte is headed by visiting Vaxcyte's forecast page.

What is Vaxcyte's operating income?

Vaxcyte's total operating income in 2024 was -$569.55 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $569.55 million

How has Vaxcyte revenue changed over the last 6 years?

Over the last 6 years, Vaxcyte's total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Vaxcyte have?

Vaxcyte's total liabilities were at $205.50 million at the end of 2024, a 22.7% increase from 2023, and a 1,647.3% increase since 2019.

How much cash does Vaxcyte have?

In the past 5 years, Vaxcyte's cash and equivalents has ranged from $58.98 million in 2019 to $834.66 million in 2022, and is currently $387.88 million as of their latest financial filing in 2024.

How has Vaxcyte's book value per share changed over the last 6 years?

Over the last 6 years, Vaxcyte's book value per share changed from 0.00 in 2018 to 26.52 in 2024, a change of 2,652.4%.

Related Companies

This page (NASDAQ:PCVX) was last updated on 6/11/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Financials

Frequently Asked Questions About Vaxcyte's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxcyte (PCVX) Financials

Annual Income Statements for Vaxcyte

Quarterly Income Statements for Vaxcyte

Annual Cash Flow Statements for Vaxcyte

Quarterly Cash Flow Statements for Vaxcyte

Annual Balance Sheets for Vaxcyte

Quarterly Balance Sheets for Vaxcyte

Annual Metrics And Ratios for Vaxcyte

Quarterly Metrics And Ratios for Vaxcyte

Frequently Asked Questions About Vaxcyte's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools